Surmodics Stock Forecast, Price & News

-0.59 (-1.08 %)
(As of 07/22/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume21,453 shs
Average Volume35,884 shs
Market Capitalization$750.37 million
P/E Ratio104.04
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SRDX News and Ratings via Email

Sign-up to receive the latest news and ratings for Surmodics and its competitors with MarketBeat's FREE daily newsletter.

Surmodics logo

About Surmodics

Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. The company operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications. The Vitro Diagnostics segment designs, develops, and manufactures component products and technologies for diagnostic immunoassay, as well as molecular test and biomedical research applications. This segment offers protein stabilization reagents, substrates, surface coatings, and antigens. Surmodics, Inc. was founded in 1979 and is headquartered in Eden Prairie, Minnesota.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

1.71 out of 5 stars

Medical Sector

276th out of 2,216 stocks

Surgical & Medical Instruments Industry

26th out of 181 stocks

Analyst Opinion: 2.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Surmodics (NASDAQ:SRDX) Frequently Asked Questions

Is Surmodics a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Surmodics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Surmodics stock.
View analyst ratings for Surmodics
or view top-rated stocks.

What stocks does MarketBeat like better than Surmodics?

Wall Street analysts have given Surmodics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Surmodics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Surmodics?

Surmodics saw a decline in short interest in the month of June. As of June 15th, there was short interest totaling 401,000 shares, a decline of 15.0% from the May 31st total of 472,000 shares. Based on an average trading volume of 46,600 shares, the days-to-cover ratio is currently 8.6 days. Currently, 3.0% of the company's stock are short sold.
View Surmodics' Short Interest

When is Surmodics' next earnings date?

Surmodics is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Surmodics

How were Surmodics' earnings last quarter?

Surmodics, Inc. (NASDAQ:SRDX) issued its quarterly earnings results on Wednesday, April, 28th. The company reported $0.62 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.60 by $0.02. The business had revenue of $35 million for the quarter, compared to analyst estimates of $35.02 million. Surmodics had a trailing twelve-month return on equity of 7.00% and a net margin of 6.86%.
View Surmodics' earnings history

How has Surmodics' stock price been impacted by Coronavirus?

Surmodics' stock was trading at $29.91 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SRDX shares have increased by 80.9% and is now trading at $54.10.
View which stocks have been most impacted by COVID-19

What guidance has Surmodics issued on next quarter's earnings?

Surmodics updated its FY 2021 earnings guidance on Wednesday, May, 5th. The company provided EPS guidance of 0.100-0.350 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.370. The company issued revenue guidance of $101 million-$105 million, compared to the consensus revenue estimate of $101.48 million.

What price target have analysts set for SRDX?

2 equities research analysts have issued twelve-month target prices for Surmodics' stock. Their forecasts range from $61.00 to $70.00. On average, they expect Surmodics' share price to reach $65.50 in the next twelve months. This suggests a possible upside of 21.1% from the stock's current price.
View analysts' price targets for Surmodics
or view top-rated stocks among Wall Street analysts.

Who are Surmodics' key executives?

Surmodics' management team includes the following people:
  • Mr. Gary R. Maharaj, CEO, Pres & Director (Age 58, Pay $1.13M)
  • Mr. Timothy J. Arens, Sr. VP of Fin. & Information Technology and CFO (Age 54, Pay $509.4k)
  • Ms. Teryl L. W. Sides, Sr. VP of Product Devel. & Chief Marketing Officer (Age 52, Pay $538.71k)
  • Mr. Joseph J. Stich, Sr. VP & GM of HR - In Vitro Diagnostics (Age 56, Pay $508.75k)
  • Mr. John D. Manders, Corp. Controller & Principal Accounting Officer (Age 40)
  • Mr. Gordon S. Weber, Sr. VP of Legal, Gen. Counsel & Sec. (Age 58)
  • Mr. Charles W. Olson, Sr. VP of Commercial & Bus. Devel. - Medical Devices (Age 57)
  • Mr. Gregg S. Sutton, VP of R&D - Medical Devices (Age 61)

What is Gary Maharaj's approval rating as Surmodics' CEO?

8 employees have rated Surmodics CEO Gary Maharaj on Gary Maharaj has an approval rating of 65% among Surmodics' employees.

Who are some of Surmodics' key competitors?

What other stocks do shareholders of Surmodics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Surmodics investors own include Gilead Sciences (GILD), Netflix (NFLX), Exelixis (EXEL), Intel (INTC), NVIDIA (NVDA), Tandem Diabetes Care (TNDM), uniQure (QURE), Sangamo Therapeutics (SGMO), Abbott Laboratories (ABT) and Dynavax Technologies (DVAX).

What is Surmodics' stock symbol?

Surmodics trades on the NASDAQ under the ticker symbol "SRDX."

Who are Surmodics' major shareholders?

Surmodics' stock is owned by a variety of retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.07%). Company insiders that own Surmodics stock include Charles W Olson, Gary R Maharaj, Jose H Bedoya and Joseph J Stich.
View institutional ownership trends for Surmodics

Which institutional investors are buying Surmodics stock?

SRDX stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue.
View insider buying and selling activity for Surmodics
or or view top insider-buying stocks.

How do I buy shares of Surmodics?

Shares of SRDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Surmodics' stock price today?

One share of SRDX stock can currently be purchased for approximately $54.10.

How much money does Surmodics make?

Surmodics has a market capitalization of $750.37 million and generates $94.86 million in revenue each year. The company earns $1.12 million in net income (profit) each year or $0.13 on an earnings per share basis.

How many employees does Surmodics have?

Surmodics employs 370 workers across the globe.

When was Surmodics founded?

Surmodics was founded in 1979.

What is Surmodics' official website?

The official website for Surmodics is

Where are Surmodics' headquarters?

Surmodics is headquartered at 9924 WEST 74TH STREET, EDEN PRAIRIE MN, 55344.

How can I contact Surmodics?

Surmodics' mailing address is 9924 WEST 74TH STREET, EDEN PRAIRIE MN, 55344. The company can be reached via phone at 952-500-7000 or via email at [email protected]

This page was last updated on 7/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.